Prevention of CF Exacerbation in Childhood: PREVEC Study (PREVEC)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01241890|
Recruitment Status : Completed
First Posted : November 16, 2010
Last Update Posted : July 17, 2015
|Condition or disease|
|Cystic Fibrosis Children Exhaled Breath Condensate Non-invasive Inflammatory Markers Volatile Organic Compounds Home Monitoring Quality of Life|
|Study Type :||Observational|
|Actual Enrollment :||49 participants|
|Official Title:||Prevention of CF Exacerbation in Childhood (PREVEC): Early Recognition of Inflammation by Non-invasive Biomarkers in Exhaled Breath (Condensate)|
|Study Start Date :||October 2011|
|Actual Primary Completion Date :||August 2013|
|Actual Study Completion Date :||July 2014|
Children with Cystic Fibrosis, care as usual
Treatment according to the Dutch Central Guidance Committee (CBO) guidelines for CF. Assessments: home monitoring, symptoms, lung function, quality of life and diagnostic assessments of non-invasive inflammatory markers in exhaled air and exhaled breath condensate.
- Number of exacerbations [ Time Frame: 1 year ]Definition of an exacerbation according to Treggiari MM et al.
- Quality of life [ Time Frame: 1 year ]Quality of life questionnaire
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01241890
|Academic Medical Centre|
|Maastricht University Medical Centre|
|University Medical Centre|
|Principal Investigator:||E Dompeling, PhD MD||Maastricht University Medical Centre|